香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 承董事會命 健倍苗苗（保 健）有限公司 公司秘書 余振球 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 執行董事辭任 及 授權代表變更 健倍苗苗（保 健）有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董事會（「董 事 會」）宣 佈，為 專 注 於 本 集 團 業 務 發 展，黃 一 偉 先 生（「黃先生」）已辭任本公司 執行董事（「執行董事」），並 不 再 擔 任 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）證 券 上市規則第3.05條項下規定的本公司授權代表（「授權代表」），自 二 零 二 五 年 七 月 八 日 起 生 效。於 上 述 辭 任 後，黃 先 生 將 留 任 本 公 司 行 政 總 裁。 黃 先 ...

(Stock Code 股份代號：2161) （於開曼群島註冊成立的有限公司） JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) (Incorporated in the Cayman Islands with limited liability) The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.jbmhealthcare.com.hk and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communica ...

JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) (Incorporated in the Cayman Islands with limited liability) (Stock Code 股份代號：2161) （於開曼群島註冊成立的有限公司） It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the above-mentioned address ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 股東週年大會通告 「動 議： – 2 – (b) 根據上文(a)段 的 授 權 可 購 回 的 本 公 司 股 份 總 數，不 得 超 過 本 公 司 於 本決議案通過當日已發行股份（不 包 括 任 何 庫 存 股 份）總數的10%（倘 於 通 過 本 決 議 案 日 期 後，本 公 司 股 份 如 有 任 何 合 併 或 分 拆，則 需 作 出 調 整）； (c) 本決議案(a)段 的 批 准 乃 附 加 於 給 予 本 公 司 董 事 的 任 何 其 他 授 權，並 授權本公司董事代表本公司於有關期間（定 義 見 下 文(d)段）內促使本 公 司 按 本 公 司 董 事 所 釐 定 的 價 格 購 ...

此乃要件 請即處理 閣下如 對本通函任何方面或應採取的行動 有任何疑問，應諮詢股票經紀或其他持牌證券 交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 名下所有健倍苗苗（保健）有 限 公 司 的 股 份，應 立 即 將 本 通 函 連 同 隨 附的代表委任表格交予買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 函 全 部 或 任 何 部 份 內 容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 （於開曼群島註冊成立的有限公司） （股份代號：2161） ( ) (1)建議重選董事 及 (2)建議授出購回股份以及發行股份及 出售庫存股份的 一般授權 及 (3)股東週年大會通告 健倍苗苗（保健）有限公司謹訂於二零二五年七月二十八日（星期一）上午十時正透過Vistra 卓佳電子投票系統以網 ...

Financial Performance - Revenue increased by 20.7% to HKD 782,292,000 compared to HKD 648,415,000 in the previous year[20] - Gross profit grew by 22.4% to HKD 413,707,000, with a gross margin of 52.9%[20] - Profit attributable to equity holders surged by 51.2% to HKD 197,261,000, resulting in a profit margin of 25.2%[20] - Adjusted EBITDA rose by 37.2% to HKD 295,762,000, with an adjusted EBITDA margin of 37.8%[20] - Total assets increased by 11.3% to HKD 1,545,118,000, while total liabilities rose by 3.9% to HKD 381,160,000[22] - The brand pharmaceutical business revenue increased to HKD 782.3 million, representing a year-on-year growth of 20.7%[42] - Gross profit grew by 22.4% to HKD 413.7 million, while profit attributable to equity holders surged by 51.2% to HKD 197.3 million[42] - Total revenue for the fiscal year 2025 increased by HKD 133.9 million or 20.7% compared to fiscal year 2024, reaching HKD 782.3 million[104] - The brand pharmaceutical segment saw a significant growth of 43.2%, contributing HKD 272.2 million to total revenue[104] Market Segments and Growth - The health supplement segment saw a 44.9% increase in revenue, reflecting strong consumer demand[20] - The flagship brand, He Ji Gong, achieved significant growth through targeted marketing, enhancing market penetration[30] - The brand Chinese medicine segment, including Bao Ji Wan and Fei Ying Huoluo Oil, performed well despite a challenging retail environment[30] - The health supplements division recorded stable growth driven by the adoption of the "Oncotype DX" breast cancer tumor gene expression test among healthcare professionals in Hong Kong and Macau[47] - The concentrated Chinese medicine granules business continues to maintain resilience, supported by stable quality and reliable supply, gaining trust from Hong Kong TCM practitioners[46] - The brand Chinese medicine segment achieved a growth of 5.0%, driven by flagship products Bao Ji Wan and Fei Ying Huo Luo You[73] - The health supplement segment experienced a substantial revenue growth of 44.9% due to the expansion of cross-border e-commerce platforms[104] Strategic Initiatives - The company is focused on strategic marketing and consumer engagement to build brand value and drive sales growth[30] - The acquisition of Tianxi Tang Pharmaceutical is expected to enhance the brand's product portfolio and create greater synergy through integration with existing operations[32] - The company is focusing on integrating online and offline sales channels while expanding e-commerce coverage and optimizing costs[42] - The company plans to diversify its development into new categories such as medical devices and strengthen its B2B and B2C sales networks[48] - The company aims to expand cross-border e-commerce channels and deepen market penetration in the Greater Bay Area[48] - The company is committed to maintaining a robust financial foundation while enhancing brand management capabilities and expanding its product portfolio[49] Brand and Marketing Achievements - The flagship brand He Ji Gong achieved significant growth, supported by strategic marketing initiatives including sponsorship of popular TV shows[44] - The marketing campaign for "飛鷹活絡油" increased brand awareness by three times through innovative advertising and strategic sponsorships[46] - The company has received multiple accolades, including the "Outstanding Marketing Award" and "Outstanding TV Advertisement Award" at the 2024 HKMA-ViuTV-Now TV Awards[44] - The brand "保濟丸" received the "2024 Hong Kong Brand Ten-Year Achievement Award" for its sustained reputation and brand value enhancement efforts[46] - The strong performance of the Baijuan brand reflects successful strategic marketing efforts, establishing deep brand value among local consumers and mainland visitors[76] Financial Management and Governance - The company maintains a robust cash position, supporting future growth and stability[29] - The company maintains a robust financial position with sufficient cash reserves, supporting ongoing operations and strategic growth plans[68] - The group maintained a conservative capital management approach, ensuring a solid foundation for future business development and acquisitions[125] - The company has adhered to all corporate governance code provisions during the reporting period[136] - The board consists of eight members, including four executive directors, one non-executive director, and three independent non-executive directors[140] - The audit committee, composed of three independent non-executive directors, is responsible for overseeing the integrity and accuracy of the company's financial statements and risk management systems[157][158] Risk Management - The risk management framework is guided by a "three lines of defense" model, ensuring effective risk management and internal controls[190] - The company employs a mixed approach to risk identification, categorizing risks into financial, operational, reputational, legal, regulatory, and personnel risks[197] - The board has reviewed the effectiveness of the risk management and internal control systems and considers them adequate and effective[198] - Internal audit reports are prepared by external consultants and presented to the audit committee[200]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 須予披露交易 收購目標集團 收購事項 於二零二五年六月十六日（交 易 時 段 結 束 後），買 方（本 公 司 的 間 接 全 資 附 屬 公 司）與 賣 方 訂 立 買 賣 協 議，據 此，買 方 有 條 件 同 意 收 購 而 賣 方 有 條 件 同 意 出售銷售股份（即 目 標 公 司 全 部 已 發 行 股 本），根 據 買 賣 協 議 的 條 款 及 條 件， 總代價為38,000,000港 元（可 予 調 整）。 上市規則的涵義 由於有關收購事項的一項或多項適用百分比率高於5%，但 所 有 有 關 比 率 均 低 於25%，故 根 據 上 市 規 則 第 十 四 章，收 購 事 項 構 成 ...

EF001 | 其他信息 | | --- | | 其他信息 不適用 | | 發行人董事 | | 於本公告日期，董事會由執行董事岑廣業先生（亦為主席）、嚴振亮先生、黃一偉先生（亦為行政總裁）及鄭香郡博士；非執行董 事楊國晉先生；以及獨立非執行董事陳錦釗先生、陸庭龍先生及劉述理先生組成。 | 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 健倍苗苗(保健 )有限公司 | | 股份代號 | 02161 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年三月三十一日止年度的末期股息 | | 公告日期 | 2025年6月12日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | ...

Financial Performance - For the fiscal year ending March 31, 2025, the company's revenue was approximately HKD 782.3 million, an increase of about 20.7% compared to HKD 648.4 million in the same period of 2024[2]. - Operating profit for the same period was approximately HKD 246.1 million, representing a growth of about 41.3% from HKD 174.2 million in 2024[2]. - Profit attributable to equity holders was approximately HKD 197.3 million, up by 51.2% from HKD 130.5 million in the previous year[2]. - The company reported a gross profit of HKD 413.7 million, compared to HKD 338.1 million in 2024, indicating a strong growth in profitability[3]. - The total comprehensive income for the year was HKD 192.6 million, compared to HKD 130.9 million in the previous year[4]. - Basic and diluted earnings per share increased to HKD 24.08 from HKD 14.76 in 2024[4]. - The adjusted EBITDA for the year was HKD 295,762,000, compared to HKD 215,496,000 in the prior year, reflecting an increase of approximately 37.2%[23]. - The company's profit before tax for the year ended March 31, 2025, was HKD 197,261,000, an increase from HKD 130,463,000 in 2024, representing a growth of approximately 51%[31]. - Basic earnings per share for the year ended March 31, 2025, were HKD 240.00, compared to HKD 147.00 in 2024, reflecting a year-over-year increase of 63.3%[31]. - The company's total income tax expense for the year ended March 31, 2025, was HKD 42,237,000, compared to HKD 27,680,000 in 2024, representing a year-over-year increase of 52.7%[7]. Dividends - The board proposed a final dividend of HKD 0.115 per share, totaling approximately HKD 94.5 million, compared to HKD 0.0405 per share in 2024[2]. - Total dividends for the fiscal year amounted to HKD 0.170 per share, significantly higher than HKD 0.075 per share in 2024[2]. - The interim dividend declared was HKD 5.5 cents per share, up from HKD 3.45 cents per share in the previous year, marking a 59.4% increase[33]. - The proposed final dividend is HKD 11.5 cents per share, compared to HKD 4.05 cents per share in 2024, indicating an increase of 184.6%[33]. Assets and Liabilities - Non-current assets totaled HKD 1,092.8 million, slightly down from HKD 1,021.2 million in 2024[5]. - Current assets included cash and cash equivalents of HKD 205.8 million, an increase from HKD 140.8 million in the previous year[5]. - Non-current liabilities decreased from HKD 145,183,000 in 2024 to HKD 100,149,000 in 2025, primarily due to a reduction in lease liabilities from HKD 43,800,000 to HKD 8,829,000[6]. - Deferred tax liabilities increased significantly from HKD 7,099,000 in 2024 to HKD 91,320,000 in 2025, indicating a potential change in tax strategy or asset valuation[6]. - Total equity rose from HKD 1,021,944,000 in 2024 to HKD 1,163,958,000 in 2025, reflecting a strong financial position and retained earnings growth[6]. - The company's capital and reserves increased, with total reserves growing from HKD 962,364,000 in 2024 to HKD 1,073,879,000 in 2025, indicating effective management of shareholder equity[6]. - The company reported a total equity attributable to equity holders of the company of HKD 1,082,019,000 in 2025, up from HKD 970,676,000 in 2024, showcasing improved shareholder value[6]. Revenue Segments - Revenue from the Brand Drug segment was HKD 272,231,000 for the year ended March 31, 2025, up from HKD 190,108,000, reflecting a growth of approximately 43.2%[22]. - The Brand Chinese Medicine segment generated revenue of HKD 405,448,000, an increase from HKD 386,122,000, showing a growth of about 5.4%[22]. - The Health Supplements segment reported revenue of HKD 104,613,000, compared to HKD 72,185,000, marking a significant increase of approximately 45.0%[22]. - Revenue from external customers in Hong Kong was HKD 562,006,000, while revenue from Mainland China was HKD 146,980,000, down from HKD 462,829,000, indicating a decline of about 68.3%[25]. Market and Growth Strategies - The company successfully captured growth opportunities in key cities within Hong Kong, Macau, and the Greater Bay Area[44]. - The company remains optimistic about growth prospects due to structural trends such as increased health awareness and an aging population driving demand for healthcare products[50]. - The company is focusing on diversifying its product portfolio to meet changing consumer demands and leveraging opportunities in the Greater Bay Area[50]. - The company is strategically positioned to benefit from increased public trust and broader market acceptance of traditional Chinese medicine, supported by favorable government policies[99]. - The company is expanding its distribution network and enhancing consumer interaction to promote brand awareness and customer base growth for Tianxi Tang products[102]. Marketing and Brand Recognition - The company received multiple awards for its marketing strategies, including the "Outstanding Television Advertising Award" and "Market Planning Award" in Hong Kong[46][47]. - The brand "He Ji Gong" ranked among the top ten best-selling overseas pharmaceutical products during the Double Eleven shopping festival in 2024, enhancing brand recognition in mainland China[49]. - The comprehensive marketing campaign for Feiying Huoluo Oil increased brand awareness threefold, positioning it as a top competitor in the medicinal oil category[59]. - The brand's marketing achievements were recognized with awards, including the "Outstanding Marketing Planning Award" and "Outstanding Television Advertising Award," enhancing brand visibility[74]. Challenges and Risks - The company anticipates challenges in FY2025 due to macroeconomic factors, including high global interest rates and ongoing US-China trade tensions, which may impact consumer sentiment and discretionary spending[97]. - The changing behavior of mainland Chinese tourists has impacted retail recovery, with shorter stays and reduced spending per visit[67]. - The retail environment in Hong Kong faced challenges, with overall sales and online sales declining due to high interest rates and changing consumer behavior[54]. - The company identified significant risks including competition in the healthcare market and potential product liability claims[137]. Corporate Governance - The audit committee consists of three independent non-executive directors, responsible for overseeing the integrity of the company's financial statements[145]. - The board of directors includes both executive and independent non-executive members, ensuring a diverse governance structure[151]. - The company has complied with all corporate governance codes throughout the reporting period[143].

JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 董事名單與其角色及職能 健倍苗苗（保 健）有限公司董事會（「董事會」）成員及其各自於董事會以及董事委 員 會 自 二 零 二 五 年 六 月 十 二 日 起 的 角 色 及 職 能 載 列 如 下： 審核委員會 薪酬委員會 提名委員會 執行委員會 董事會主席兼執行董事 岑廣業先生 C C 執行董事 嚴振亮先生 M M 黃一偉先生（行 政 總 裁） 鄭香郡博士 非執行董事 楊國晉先生 M 獨立非執行董事 陳錦釗先生 MMM 陸庭龍先生 CCM 劉述理先生 MMM 附 註： C： 相關董事委員會主席 M： 相關董事委員會成員 香 港，二 零 二 五 年 六 月 十 二 日 ...